Clinical Manifestations and Outcomes of 20 Korean Hypochondroplasia Patients with the FGFR3 N540K variant
Experimental and Clinical Endocrinology & Diabetes · 01.03.2023 · 131 (03) · 123-131
DOI: 10.1055/a-1988-9734 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, erschienen am 01.03.2023. Verfasst von Hwa Young Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Korea. Hauptthemen laut MEDLINE: Achondroplasia, Human Growth Hormone, Osteochondrodysplasias. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Background
Hypochondroplasia is a skeletal dysplasia caused by activating pathologic variants of FGFR3. The N540K variant accounts for 60–70% of reported cases and is associated with severe manifestations. Here, we analyze the clinical manifestations and outcomes of Korean patients with hypochondroplasia harboring the FGFR3 N540K variant.
Methods
Medical records of 20 unrelated patients with genetically confirmed N540K-related hypochondroplasia were retrospectively reviewed. All individuals were diagnosed with hypochondroplasia by Sanger sequencing for FGFR3, or target-panel sequencing for skeletal dysplasia. The effectiveness of growth hormone therapy was analyzed in 16 patients treated with growth hormones.
Results
Among 20 patients (7 men, 13 women), the mean age at first visit was 3.5±1.0 years, and the mean follow-up duration was 6.8±0.6 years. The patients presented with a short stature and/or short limbs. Genu varum, macrocephaly, and developmental delay were observed in 11 (55.0%), 9 (45.0%), and 5 (25.0%) patients, respectively. Of the 12 patients who underwent neuroimaging, five (41.7%) showed abnormal findings (one required operation for obstructive hydrocephalus). Among 16 growth-hormone-treated patients (two were growth-hormone deficient), the increase in height standard deviation scores was significant after a mean 5.4±0.7 years of treatment (+0.6 and+1.8 using growth references for healthy controls and achondroplasia children, respectively). Four patients underwent surgical limb lengthening at a mean age of 8.8±3.3 years.
Conclusions
Neurodevelopmental abnormalities are frequently observed in patients with N540K-related hypochondroplasia. Close monitoring of skeletal manifestations and neurodevelopmental status is necessary for hypochondroplasia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Korea.
- Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
- Department of Orthopaedics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
- Rare Disease Center, Seoul National University Hospital, Seoul, Korea.
Zitieren
APA
Kim, H. Y., Lee, Y. A., Shin, C. H., Cho, T. J., & Ko, J. M. (2023). Clinical Manifestations and Outcomes of 20 Korean Hypochondroplasia Patients with the FGFR3 N540K variant. Experimental and Clinical Endocrinology & Diabetes, 131(03), 123-131. https://doi.org/10.1055/a-1988-9734
Vancouver
Kim HY, Lee YA, Shin CH, Cho TJ, Ko JM. Clinical Manifestations and Outcomes of 20 Korean Hypochondroplasia Patients with the FGFR3 N540K variant. Experimental and Clinical Endocrinology & Diabetes. 2023;131(03):123-131. doi:10.1055/a-1988-9734
BibTeX
@article{Kim2023,
author = {Kim, Hwa Young and Lee, Young Ah and Shin, Choong Ho and Cho, Tae-Joon and Ko, Jung Min},
title = {Clinical Manifestations and Outcomes of 20 Korean Hypochondroplasia Patients with the FGFR3 N540K variant},
journal = {Experimental and Clinical Endocrinology & Diabetes},
year = {2023},
volume = {131},
number = {03},
pages = {123--131},
doi = {10.1055/a-1988-9734}
}
EUVIMED